These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 89620)

  • 61. Elimination of human immunodeficiency virus from immunoglobulin preparations.
    Lancet; 1986 May; 1(8491):1217-8. PubMed ID: 2422515
    [No Abstract]   [Full Text] [Related]  

  • 62. [Content of antibodies to certain cardiotropic strains of enteral viruses in commercial gamma-globulin preparations].
    Venediktova NIa; Khovanova AM; Kolpakova VE; Patsuk NV; Deĭch SB
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Aug; (8):147-8. PubMed ID: 53971
    [No Abstract]   [Full Text] [Related]  

  • 63. [Virus infection in the clinic].
    Goetz O
    Monatsschr Kinderheilkd (1902); 1977 May; 125(5):273-5. PubMed ID: 69260
    [No Abstract]   [Full Text] [Related]  

  • 64. Additional commercial gammaglobulin preparations found with antibody to human immunodeficiency virus.
    Hausler WJ; Swack NS; Ramirez MT
    J Infect Dis; 1990 Jan; 161(1):153. PubMed ID: 1688600
    [No Abstract]   [Full Text] [Related]  

  • 65. [Inherent specific immunity as basis for preventive and therapeutic use of homologous antibodies].
    AUERSWALD W
    Wien Z Inn Med; 1954 Apr; 35(4):157-63. PubMed ID: 13196374
    [No Abstract]   [Full Text] [Related]  

  • 66. Immune thrombocytopenia gammaglobulin, and positivity to the human T-lymphotropic virus type III.
    Laurian Y; Le Bras P; Ellrodt A; Alvin P
    Ann Intern Med; 1986 Jul; 105(1):145-6. PubMed ID: 2424352
    [No Abstract]   [Full Text] [Related]  

  • 67. [Tolerance of a new intravenously applied immunoglobulin preparation and its effect on serum globulin levels].
    Hansi W; Heimpel H; Barandun S; Lutz O
    Infection; 1982; 10(6):347-51. PubMed ID: 6185438
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Problems of intravenous gammaglobulin therapy (author's transl)].
    Ring J; Duswald KH
    Klin Wochenschr; 1980 Aug; 58(16):797-809. PubMed ID: 6161272
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Neutralizing virus antibodies in human immunoglobulins for intravenous use].
    Weeke-Lüttmann M; Schmidt I; Fenyves A; von Wangenheim G; Fischer L
    Immun Infekt; 1984 Aug; 12(4):201-7. PubMed ID: 6090309
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Viral antibody content in gamma globulin].
    Brodersen M; Haas R; Schmitz H; Veres-Molnar S; Fischer J; Körner L
    Dtsch Med Wochenschr; 1970 May; 95(22):1229-31. PubMed ID: 4193235
    [No Abstract]   [Full Text] [Related]  

  • 71. Purity, anticomplementary activity, and viral antibody profile of NIG preparations for intravenous and intramuscular use.
    Scheiermann N; Kuwert EK
    Dev Biol Stand; 1979; 44():165-71. PubMed ID: 544291
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunoglobulin idiotypes: analysis of viral antigen-antibody systems.
    Kennedy RC; Dreesman GR
    Prog Med Virol; 1985; 31():168-82. PubMed ID: 2578680
    [No Abstract]   [Full Text] [Related]  

  • 73. [Studies on human immunoglobulin preparations: I. Viral antibody profiles (author's transl)].
    Scheiermann N; Kuwert EK
    Med Klin; 1979 May; 74(21):820-4. PubMed ID: 89620
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.